Recruiting EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC NCT07637448 Conditions Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +10 more Locations Southern Medical University Nanfang Hospital Department of Oncology — Guangzhou, Guangdong, China View Trial Details
Recruiting Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer NCT05554276 Conditions Cervical Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +14 more Locations Vitalbeam — Shanghai, China View Trial Details
Not Yet Recruiting L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH NCT05775705 Conditions DNA Virus Infections, Epstein-Barr Virus, Epstein-Barr Virus Infections, +17 more Locations Beijing Friendship Hospital, Capital Medical University — Beijing, Beijing Municipality, China View Trial Details
Completed DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma NCT04834674 Conditions Adenocarcinoma, Apatinib, Carcinoma, +7 more Locations Sichuan Cancer Hospital and Research Institute — Chengdu, Sichuan, China View Trial Details
Completed Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC NCT04507217 Conditions Brain Diseases, Brain Metastases, Brain Neoplasms, +16 more Locations Cancer Center of Sun-Yat Sen University (CCSYSU) — Guangzhou, Guangdong, China Guangxi Medical University Affiliated Tumor Hospital — Nanning, China View Trial Details
